American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors

NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced that the American Foregut Society's (AFS) 2024 Annual Meeting, being held from September 26-28, 2024 at the Gaylord Rockies Resort & Convention Center in Aurora, CO, will be highlighting its EsoGuard^® Esophageal DNA Test for early detection of esophageal precancer to conference participants.

During the meeting, Dan Lister, M.D., current President-elect and one of the co-founders of the AFS, will lead a session titled "Finding Barrett's - Time to Ditch the Scope?" where he will discuss the value and utility of EsoGuard as a highly effective non-invasive alternative to screening upper endoscopy (EGD) for detecting esophageal precancer (Barrett's Esophagus or BE). This session follows the AFS's recent open letter, which highlights the critical need for early detection of esophageal precancer to prevent highly lethal esophageal cancer and strongly advocates for medical policy coverage of EsoGuard by commercial payors. The letter emphasizes the strong scientific evidence supporting the use of EsoGuard as a minimally invasive alternative to screening EGD and its incorporation in the practices of AFS physicians. Dr. Lister's session will explore how EsoGuard serves as a powerful tool to triage at-risk patients, thus enabling more efficient use of endoscopy resources while enabling effective early detection of esophageal precancer and facilitating surveillance and treatment to prevent progression to cancer.

"We are honored to once again participate in the AFS Annual Meeting, especially following their recent strong endorsement of EsoGuard," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We are grateful to the AFS and its leaders, including Dr. Lister, for their vocal advocacy in support of esophageal precancer testing to prevent esophageal cancer, and the critical role EsoGuard is playing as the first and only commercially available non-endoscopic biomarker test designed to do so. We have been proud to support the AFS since its inception and appreciate their efforts at the vanguard of esophageal health and cancer prevention."

The AFS Annual Meeting is a premier event that brings together gastroenterologists and surgeons to collaborate on personalizing treatment and improving patient outcomes for foregut diseases. The conference covers a wide range of topics, including diagnostics, novel therapies, and the latest advancements in foregut health.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report.  Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

SOURCE Lucid Diagnostics